Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Blood (2024) 144 (17): 1813–1820.

https://doi.org/10.1182/blood.2024025802

Published: 2024

Journal Articles

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 4576.

https://doi.org/10.1182/blood-2023-187092

Published: 2023

Journal Articles

Role of Splenic Irradiation Prior to Transplant for Myelofibrosis: A Global Collaboration

Nico Gagelmann, Gabriela S. Hobbs, Edoardo Campodonico, Polona Novak, Vaneuza Funke, Vanderson Rocha, Nelson Hamerschlak, Thomas Schroeder, Christina Rautenberg, Linette Bosques, Raffaella Greco, Artur Schneider, Grzegorz Helbig, Nicolaus Kroeger

Blood (2023) 142 (Supplement 1): 2152.

https://doi.org/10.1182/blood-2023-191300

Published: 2023

Journal Articles

Psychiatric and Substance Use Disorders Are Independent Predictors of Treatment Response and Outcomes in United States Veterans with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Combinations

Michelle Hyunju Lee, Jennifer La, Mary T Brophy, Nhan V Do, Camille V. Edwards, Clark Dumontier, Gabriela S. Hobbs, Nathanael R Fillmore

Blood (2023) 142 (Supplement 1): 388.

https://doi.org/10.1182/blood-2023-180915

Published: 2023

Journal Articles

Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes

Joan How, Orly Leiva, Anna E. Marneth, Baransel Kamaz, Chulwoo J. Kim, Lachelle D. Weeks, Mohammed Wazir, Maximilian Stahl, Daniel J. DeAngelo, R. Coleman Lindsley, Marlise R. Luskin, Gabriela S. Hobbs

Blood (2023) 142 (Supplement 1): 4568.

https://doi.org/10.1182/blood-2023-179324

Published: 2023

Journal Articles

Myelofibrosis Is Associated with Poor Cardiovascular Outcomes after Heart Failure Hospitalization

Orly Leiva, Jose Alvarez-Cardona, Andrew M. Brunner, Chi-Joan How, Gabriela S. Hobbs

Blood (2023) 142 (Supplement 1): 3203.

https://doi.org/10.1182/blood-2023-173589

Published: 2023

Journal Articles

A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Manik Razdan Kuchroo, Robert A. Redd, Jacqueline S. Garcia, Michael Keng, Gabriela S. Hobbs, Jacalyn Rosenblatt, Marlise R. Luskin, Rupa Narayan, Philip C. Amrein, Malgorzata McMasters, Martha Wadleigh, Hanno Hock, Richard Stone, Donna S. Neuberg, David Avigan, Karen K. Ballen, Amir T. Fathi, Daniel J. DeAngelo, Andrew M. Brunner

Blood (2023) 142 (Supplement 1): 2894.

https://doi.org/10.1182/blood-2023-188182

Published: 2023

Journal Articles

Changes in White Blood Cell Counts Early during Treatment of Acute Leukemia Using Differentiating Chemotherapies

Amyah C. Harris, Christopher S. Bell, Gabriela S. Hobbs, Hanno Hock, Philip C. Amrein, Rupa Narayan, Amir T. Fathi, Andrew M. Brunner

Blood (2023) 142 (Supplement 1): 1486.

https://doi.org/10.1182/blood-2023-187367

Published: 2023

Journal Articles

Maintenance Ruxolitinib Is Associated with Low Rates of Chronic Gvhd Requiring Systemic Treatment in Older Adults with AML/MDS Undergoing Allogeneic HCT: Results of a Phase II Multicenter Trial

Zachariah Defilipp, Haesook T. Kim, Laura Knight, Suzanne O'Connor, Meghan White, Bhagirathbhai Dholaria, Mark A. Schroeder, Sumithira Vasu, Sameem Abedin, Areej El-Jawahri, Steven McAfee, Yi-Bin Chen, Gabriela S. Hobbs

Blood (2023) 142 (Supplement 1): 653.

https://doi.org/10.1182/blood-2023-180423

Published: 2023

Journal Articles

Updated Findings of a Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Stem Cell Transplantation for Patients with Primary or Secondary Myelofibrosis

Gabriela S. Hobbs, Haesook T. Kim, Suzanne O'Connor, Mark A. Schroeder, Roni Tamari, Sarah A Wall, Areej El-Jawahri, Steven McAfee, Jessica Hem, Patricia Lozano, Jonas S. Jutzi, Ann Mullally, Yi-Bin Chen, Zachariah Defilipp

Blood (2023) 142 (Supplement 1): 2103.

https://doi.org/10.1182/blood-2023-178645

Published: 2023

Journal Articles

No Increased Incidence of Bleeding in Essential Thrombocythemia Patients with Extreme Thrombocytosis

Rathnam K. Venkat, Robert A. Redd, Martin J. Aryee, Anna E. Marneth, Baransel Kamaz, Chulwoo J. Kim, Mohammed Wazir, Lachelle D. Weeks, Maximilian Stahl, Daniel J. DeAngelo, Coleman Lindsley, Marlise R. Luskin, Gabriela S. Hobbs, Joan How

Blood (2023) 142 (Supplement 1): 1839.

https://doi.org/10.1182/blood-2023-187530

Published: 2023

Journal Articles

Myeloproliferative Neoplasms Are Associated with Increased Risk of Major Adverse Limb Events Among Patients Hospitalized for Peripheral Arterial Disease

Orly Leiva, Andrew M. Brunner, Joan How, Gabriela S. Hobbs, Jeffrey S Berger

Blood (2023) 142 (Supplement 1): 4570.

https://doi.org/10.1182/blood-2023-180783

Published: 2023

Journal Articles

Single-Cell Multiomics Analysis Reveals Potential Drivers of Response to the Anti-TIM3 Inhibitor Sabatolimab Combined with Azacitidine in MDS and CMML

Aonkon Dey, Rupa Narayan, Neal Smith, Alice Tirard, Benjamin Arnold, John McGuire, Thomas Chan, Jennifer Lombardi Story, Timothy Casson, Tanya Toni Behnan, Amir T. Fathi, Gabriela S. Hobbs, Hanno Hock, Philip C. Amrein, Patrick Reeves, Timothy Aaron Graubert, Andrew M. Brunner, Alexandra-Chloé Villani

Blood (2023) 142 (Supplement 1): 4319.

https://doi.org/10.1182/blood-2023-189858

Published: 2023

Journal Articles

Development of Consensus Guidelines for Hematology Fellow Competency in Peripheral Blood Smear Review Utilizing Nominal Group Technique

Matthew L Chase, Reed E. Drews, Alfred I Lee, Erin G Reid, Aaron T. Gerds, Gabriela S. Hobbs, Leslie R Ellis, Marc S Zumberg, Jonathan Berry, Jason A Freed

Blood (2022) 140 (Supplement 1): 10781–10783.

https://doi.org/10.1182/blood-2022-159990

Published: 2022

Journal Articles

Trends in All-Cause and Cardiovascular Mortality Among Patients with Myeloproliferative Neoplasms: A Surveillance, Epidemiology, and End Results Database Analysis

Orly Leiva, Chi-Joan How, Andrew M. Brunner, Gabriela S. Hobbs

Blood (2022) 140 (Supplement 1): 6808–6809.

https://doi.org/10.1182/blood-2022-170607

Published: 2022

Journal Articles

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Blood (2022) 140 (Supplement 1): 3309–3311.

https://doi.org/10.1182/blood-2022-160100

Published: 2022

Journal Articles

Emergence of Chronic Myeloid Leukemia in Patients with Myeloproliferative Neoplasms: A Single-Institution Experience

Kevin C. Miller, Jennifer Lombardi Story, Julia Foster, Jenna A. Moran, Amir T. Fathi, Gabriela S. Hobbs

Blood (2022) 140 (Supplement 1): 12295–12296.

https://doi.org/10.1182/blood-2022-170986

Published: 2022

Journal Articles

Real-World Experience of Ropeginterferon in Myeloproliferative Neoplasm Patients

Chi-Joan How, Gabriela S. Hobbs

Blood (2022) 140 (Supplement 1): 12284–12285.

https://doi.org/10.1182/blood-2022-157076

Published: 2022

Journal Articles

Risk Factors for Major Adverse Cardiac Events and Bleeding in Patients with Myeloproliferative Neoplasms Admitted for Myocardial Infarction

Orly Leiva, Emaad Siddiqui, Gabriela S. Hobbs, Sripal Bangalore

Blood (2022) 140 (Supplement 1): 9729–9730.

https://doi.org/10.1182/blood-2022-157476

Published: 2022

Journal Articles

Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections

Joan How, Kathleen M.E. Gallagher, Yiwen Liu, Katelin Katsis, Eva Elder, Donna S. Neuberg, Patrick M. Reeves, Marcela V. Maus, Gabriela S. Hobbs

Blood (2022) 140 (Supplement 1): 6852–6853.

https://doi.org/10.1182/blood-2022-157628

Published: 2022

NARROW

Proposals for revised International Working Group–European LeukemiaNet criteria for anemia response in myelofibrosis

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Role of Splenic Irradiation Prior to Transplant for Myelofibrosis: A Global Collaboration

Psychiatric and Substance Use Disorders Are Independent Predictors of Treatment Response and Outcomes in United States Veterans with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Combinations

Cardiovascular Risk Factors Are Common in Myeloproliferative Neoplasms and Portend Worse Survival and Thrombotic Outcomes

Myelofibrosis Is Associated with Poor Cardiovascular Outcomes after Heart Failure Hospitalization

A Phase 2 Study of Lenalidomide in Combination with Mitoxantrone, Etoposide, and Cytarabine (Len plus MEC) in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Changes in White Blood Cell Counts Early during Treatment of Acute Leukemia Using Differentiating Chemotherapies

Maintenance Ruxolitinib Is Associated with Low Rates of Chronic Gvhd Requiring Systemic Treatment in Older Adults with AML/MDS Undergoing Allogeneic HCT: Results of a Phase II Multicenter Trial

Updated Findings of a Phase II Study of Ruxolitinib Pre-, during- and Post-Hematopoietic Stem Cell Transplantation for Patients with Primary or Secondary Myelofibrosis

No Increased Incidence of Bleeding in Essential Thrombocythemia Patients with Extreme Thrombocytosis

Myeloproliferative Neoplasms Are Associated with Increased Risk of Major Adverse Limb Events Among Patients Hospitalized for Peripheral Arterial Disease

Single-Cell Multiomics Analysis Reveals Potential Drivers of Response to the Anti-TIM3 Inhibitor Sabatolimab Combined with Azacitidine in MDS and CMML

Development of Consensus Guidelines for Hematology Fellow Competency in Peripheral Blood Smear Review Utilizing Nominal Group Technique

Trends in All-Cause and Cardiovascular Mortality Among Patients with Myeloproliferative Neoplasms: A Surveillance, Epidemiology, and End Results Database Analysis

Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults

Emergence of Chronic Myeloid Leukemia in Patients with Myeloproliferative Neoplasms: A Single-Institution Experience

Real-World Experience of Ropeginterferon in Myeloproliferative Neoplasm Patients

Risk Factors for Major Adverse Cardiac Events and Bleeding in Patients with Myeloproliferative Neoplasms Admitted for Myocardial Infarction

Immunologic Responses to Sars-Cov-2 Vaccination in Myeloproliferative Neoplasm Patients: Durability, Booster Responses, and Associations with Infections

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only